Table 5 Summary of parameter distributions for costs (in 2010 euros) used in the PSA
Costs of resources | Parameter | Expected costs (€) (standard error) | |||
|---|---|---|---|---|---|
After THR | After TKR | ||||
Hospital perspective | SHI perspective | Hospital perspective | SHI perspective | ||
Prophylaxis costs with enoxaparin in the case of | |||||
Post-discharge VTE or no VTE and no MB | par_14 | 0 | 106.42 (10.64) | 0 | 1.63 (0.16) |
Prophylaxis costs with rivaroxaban in the case of | |||||
MB with or without VTE | par_15 | 13.00 (1.30) | 0 | 13.00 (1.30) | 0 |
Pre-discharge VTE without MB | par_16 | 18.20 (1.82) | 0 | 18.20 (1.82) | 0 |
Post-discharge VTE or no VTE and no MB | par_17 | 32.24 (3.22) | 134.85 (13.49) | 33.02 (3.30) | 2.06 (0.21) |
Total costs of pre-discharge VTE | |||||
DVT | par_18 | 1,282.27 (128.33) | 157.35 (17.74) | 1,115.14 (111.51) | 157.40 (15.74) |
Non-fatal PE | par_19 | 2,105.22 (210.52) | 157.23 (15.73) | 2,362.79 (236.28) | 348.40 (34.84) |
Total costs of post-discharge VTE | |||||
DVT | par_20 | 0 | 1,995.89 (199.59) | 0 | 1,995.89 (199.59) |
Non-fatal PE | par_21 | 0 | 3,700.43 (370.04) | 0 | 3,700.43 (370.04) |
Fatal PE | par_22 | 0 | 1,256.43 (125.64) | 0 | 1,256.43 (125.64) |